Table 2.
Baseline characteristics
| Total | Group A | Group B | Group C | pa,b,c | |
|---|---|---|---|---|---|
| Patients (n) | 33 | 5 | 21 | 7 | |
| Age (year) | 63 (54–73) | 59 (54–77) | 65 (55–73) | 59 (54–68) | 0.456a |
| Gender (m/f) | 20/13 | 3/2 | 14/7 | ¾ | 0.812c |
| BMI (kg/m2) | 26.4 (22.6–31.2) | 22.5 (18.3–22.7) | 27.7 (24.4–31.1) | 31.3 (24.5–46.4) | 0.018b |
| WBC (/nL) | 17 (13–22) | 26 (25–34) | 14 (10–21) | 15 (11–35) | 0.190b |
| CRP (mmol/L) | 124.2 (78.3–217.3) | 88.8 (61.1–197.8) | 135 (106.9–176.8) | 114.3 (42.2–210.8) | 0.899a |
| INR | 1.38 (1.24–1.54) | 1.28 (1.24–1.54) | 1.39 (1.28–1.56) | 1.34 (1.19–1.98) | 0.584a |
| Lactate (mg/dL) | 15 (12–27) | 30 (21–55) | 15 (11–21) | 15 (13–26) | 0.114b |
| Platelets count (/nL) | 182 (104–374) | 136 (68–287) | 171 (88–310) | 335 (187–444) | 0.127a |
| Albumin (g/L) | 22.6 (19.6–25.03) | 22.9 (16.8–29.2) | 22.7 (18–25.4) | 24 (16.8–25.2) | 0.766a |
| Creatinine clearance (mL/min) | 32 (20–64) | 29 (0–75) | 32 (21–57) | 32 (25–89) | 0.606a |
| SOFA score | 9 (5–11) | 12 (11–16) | 9 (5–11) | 8 (4–10) | 0.017a |
| SAPSII score | 55 (41–72) | 57 (51–65) | 59 (39–71) | 55 (35–68) | 0.547a |
| APACHE II score | 23 (18–30) | 27 (21–34) | 25 (15–28) | 28 (19–30) | 0.698a |
| Duration of therapy (days) | 8 (6–12) | 7 (4–9) | 9 (7–14) | 6 (5–12) | 0.857b |
Data are presented as median and interquartile range (25th to 75th percentile) or frequencies
BMI: body mass index; WBC: white blood cell count; CRP: C-reactive protein; INR: international normalized ratio; SOFA: Sequential Organ Failure Assessment; SAPS: Simplified Acute Physiology Score; APACHE II: Acute Physiology and Chronic Health Evaluation; p value: comparison between group A and D: aIndependent t test, bMann–Whitney U test, cFisher’s exact test